Strs Ohio Buys Shares of 18,100 Twist Bioscience Corporation $TWST

Key Points

• Strs Ohio acquired 18,100 shares of Twist Bioscience Corporation in Q1, valued at approximately $711,000, according to its recent SEC filing.
• CEO Emily M. Leproust and CFO Adam Laponis both sold shares recently, with Leproust selling 2,265 shares for about $58,346 and Laponis selling 2,449 shares for approximately $93,429.
• Twist Bioscience reported a loss of ($0.47) EPS in its latest quarterly earnings, surpassing analyst expectations, while the company maintains a consensus rating of "Moderate Buy".

Strs Ohio purchased a new position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 18,100 shares of the company's stock, valued at approximately $711,000.

A number of other institutional investors have also recently made changes to their positions in TWST. ARK Investment Management LLC boosted its stake in Twist Bioscience by 11.5% during the first quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock worth $245,045,000 after buying an additional 645,730 shares during the last quarter. Vanguard Group Inc. boosted its stake in Twist Bioscience by 1.0% during the first quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock worth $230,356,000 after buying an additional 60,276 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Twist Bioscience by 186.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after buying an additional 1,588,587 shares during the last quarter. EdgePoint Investment Group Inc. acquired a new position in Twist Bioscience during the first quarter worth $43,705,000. Finally, Goldman Sachs Group Inc. raised its position in Twist Bioscience by 4.2% in the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company's stock valued at $36,629,000 after purchasing an additional 37,577 shares during the period.

Twist Bioscience Trading Up 0.9%

Shares of TWST stock traded up $0.26 during mid-day trading on Tuesday, hitting $28.07. 80,377 shares of the company's stock were exchanged, compared to its average volume of 1,230,728. Twist Bioscience Corporation has a fifty-two week low of $24.07 and a fifty-two week high of $55.33. The stock has a 50-day simple moving average of $29.27 and a two-hundred day simple moving average of $33.67. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -19.46 and a beta of 2.31.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The firm had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insider Transactions at Twist Bioscience

In related news, CEO Emily M. Leproust sold 2,265 shares of Twist Bioscience stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $25.76, for a total value of $58,346.40. Following the completion of the transaction, the chief executive officer directly owned 634,740 shares in the company, valued at approximately $16,350,902.40. This trade represents a 0.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Adam Laponis sold 2,449 shares of Twist Bioscience stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the transaction, the chief financial officer owned 103,569 shares of the company's stock, valued at $3,951,157.35. This trade represents a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,805 shares of company stock worth $211,868. Corporate insiders own 3.01% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on TWST shares. Cowen restated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Evercore ISI set a $46.00 price objective on Twist Bioscience in a report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $49.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.